☰

Carolyn A. Goard, Ph.D. - Publications

Affiliations: 
2013 Medical Biophysics University of Toronto, Toronto, ON, Canada 
Area:
Molecular Biology, Pharmacy
Tree Info Similar researchers PubMed Report error

12/18 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Leeuwen Jv, Pandyra A, Goard C, Mullen PJ, Yu R, Penn LZ. Abstract 3543: Targeting the metabolic mevalonate pathway with statins as anti-breast cancer agents Cancer Research. 77: 3543-3543. DOI: 10.1158/1538-7445.Am2017-3543  0.686
2015 Pandyra AA, Mullen PJ, Goard CA, Ericson E, Sharma P, Kalkat M, Yu R, Pong JT, Brown KR, Hart T, Gebbia M, Lang KS, Giaever G, Nislow C, Moffat J, et al. Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget. PMID 26353928 DOI: 10.18632/Oncotarget.4817  0.666
2015 Sriskanthadevan S, Jeyaraju DV, Chung TE, Prabha S, Xu W, Skrtic M, Jhas B, Hurren R, Gronda M, Wang X, Jitkova Y, Sukhai MA, Lin FH, Maclean N, Laister R, ... Goard CA, et al. AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. Blood. 125: 2120-30. PMID 25631767 DOI: 10.1182/Blood-2014-08-594408  0.588
2014 Xu GW, Toth JI, da Silva SR, Paiva SL, Lukkarila JL, Hurren R, Maclean N, Sukhai MA, Bhattacharjee RN, Goard CA, Medeiros B, Gunning PT, Dhe-Paganon S, Petroski MD, Schimmer AD. Mutations in UBA3 confer resistance to the NEDD8-activating enzyme inhibitor MLN4924 in human leukemic cells. Plos One. 9: e93530. PMID 24691136 DOI: 10.1182/Blood.V122.21.2527.2527  0.339
2014 Goard CA, Chan-Seng-Yue M, Mullen PJ, Quiroga AD, Wasylishen AR, Clendening JW, Sendorek DH, Haider S, Lehner R, Boutros PC, Penn LZ. Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Research and Treatment. 143: 301-12. PMID 24337703 DOI: 10.1007/S10549-013-2800-Y  0.66
2014 Goard CA, Schimmer AD. Mitochondrial matrix proteases as novel therapeutic targets in malignancy Oncogene. 33: 2690-2699. PMID 23770858 DOI: 10.1038/Onc.2013.228  0.326
2013 Goard CA, Schimmer AD. An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies. Core Evidence. 8: 15-26. PMID 23515850 DOI: 10.2147/Ce.S42568  0.432
2013 Wang Z, Dove P, Wang X, Goard CA, Li Z, Nachman A, Oh YJ, Hurren R, Ruschak A, Climie S, O'Neill D, Press B, Griffin C, Undzys E, Aman A, et al. FV-162 Is a Novel Orally Bioavailable Proteasome Inhibitor With Improved Pharmacokinetics That Displays Preclinical Efficacy In Vitro and In Vivo Blood. 122: 1988-1988. DOI: 10.1182/Blood.V122.21.1988.1988  0.359
2011 Mullen PJ, Goard CA, Wasylishen AR, Pandyra A, Penn LZ. Abstract C165: Breast cancer, statins, and 3-D cell culture. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C165  0.662
2010 Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, Sharom FJ, Penn LZ. Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. International Journal of Cancer. 127: 2936-48. PMID 21351272 DOI: 10.1002/Ijc.25295  0.56
2010 Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. Bmc Cancer. 10: 103. PMID 20298590 DOI: 10.1186/1471-2407-10-103  0.644
2010 Goard C, Gauthier M, Penn L. 169 Identifying molecular hallmarks of sensitivity to the anticancer effects of statins in breast tumour cells European Journal of Cancer Supplements. 8: 58. DOI: 10.1016/S1359-6349(10)71874-7  0.431
Low-probability matches (unlikely to be authored by this person)
2014 Jitkova Y, Gronda M, Hurren R, Wang X, Goard CA, Jhas B, Schimmer AD. A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity. Plos One. 9: e95281. PMID 24871339 DOI: 10.1371/Journal.Pone.0095281  0.289
2014 Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, Jitkova Y, Hurren R, Gronda M, Goard CA, Rajewski LG, Haslam JL, Heppert KE, Schorno K, Chang H, et al. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies. American Journal of Hematology. 89: 363-8. PMID 24273151 DOI: 10.1002/Ajh.23640  0.276
2007 Rintala-Maki ND, Goard CA, Langdon CE, Wall VE, Traulsen KE, Morin CD, Bonin M, Sutherland LC. Expression of RBM5-related factors in primary breast tissue. Journal of Cellular Biochemistry. 100: 1440-58. PMID 17131366 DOI: 10.1002/jcb.21134  0.27
2014 Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, Tallman MS, Goard C, Borthakur G. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. Plos One. 9: e108694. PMID 25285531 DOI: 10.1371/Journal.Pone.0108694  0.243
2007 Shu Y, Rintala-Maki ND, Wall VE, Wang K, Goard CA, Langdon CE, Sutherland LC. The apoptosis modulator and tumour suppressor protein RBM5 is a phosphoprotein. Cell Biochemistry and Function. 25: 643-53. PMID 16927403 DOI: 10.1002/cbf.1366  0.22
2007 Goard CA, Bromberg IL, Elliott MB, Diamandis EP. A consolidated catalogue and graphical annotation of dbSNP polymorphisms in the human tissue kallikrein (KLK) locus. Molecular Oncology. 1: 303-12. PMID 19383304 DOI: 10.1016/J.Molonc.2007.09.001  0.215
Hide low-probability matches.